The ear is not an obvious place to look for vagus nerve access, yet a small branch of the vagus — the auricular branch, known clinically as Arnold’s nerve — surfaces in the external ear and provides the only place on the body’s surface where vagal fibres can be reached without surgery. This anatomical quirk has turned a patch of ear cartilage into one of the most actively researched sites in neuromodulation.

Arnold’s Nerve: Anatomy of the Auricular Branch

The auricular branch of the vagus nerve (ABVN) splits from the main vagal trunk just below the jugular foramen and takes an unusual path — it loops through the temporal bone and emerges to innervate specific regions of the external ear. Its existence has been known since the 19th century, when Friedrich Arnold described the phenomenon of coughing triggered by cleaning the ear canal. This “Arnold’s cough reflex,” experienced by roughly 2 to 4 percent of people, is direct proof that stimulating the ear activates vagal pathways — the cough is mediated by the same vagal circuits that protect the airway.

The ABVN innervates the concha of the ear (the bowl-shaped depression leading to the ear canal), the tragus (the small flap in front of the ear canal), and parts of the posterior ear. However, the density of vagal innervation varies significantly across these regions, and this matters for anyone attempting stimulation.

Cymba Conchae: The Primary Vagal Zone

The most densely ABVN-innervated region is the cymba conchae — the upper part of the ear’s concha, the small ridge of cartilage above the ear canal opening. A 2002 cadaveric dissection study by Peuker and Filler mapped the nerve supply of the human auricle and found that the cymba conchae receives its sensory innervation almost exclusively from the ABVN, making it the purest vagal target on the ear’s surface.

The tragus, which many popular sources identify as the primary vagus nerve pressure point, actually has mixed innervation — it receives fibres from both the ABVN and the great auricular nerve (a branch of the cervical plexus, not the vagus). This means stimulating the tragus activates vagal pathways but less selectively than stimulating the cymba conchae. The earlobe receives essentially no vagal innervation and is frequently used as a sham stimulation site in clinical trials.

This anatomical distinction has direct practical implications. The most studied taVNS (transcutaneous auricular vagus nerve stimulation) devices — including the NEMOS system from Cerbomed, the first to receive CE marking for epilepsy treatment in Europe — specifically target the cymba conchae rather than the tragus.

What Happens When You Stimulate the Auricular Vagus

Stimulating the ABVN at the cymba conchae sends afferent signals through Arnold’s nerve to the nucleus tractus solitarius (NTS) in the brainstem — the same relay station that receives input from the main vagal trunk. From the NTS, signals project to the locus coeruleus (norepinephrine regulation), the dorsal raphe nucleus (serotonin regulation), and the hypothalamus (autonomic and hormonal control). Functional MRI studies have confirmed that taVNS at the cymba conchae activates these brainstem and cortical regions in patterns that closely resemble those produced by implanted cervical VNS.

Measurable physiological effects of taVNS include increased heart-rate variability (reflecting enhanced cardiac vagal tone), reduced salivary cortisol (reflecting HPA axis modulation), and decreased levels of pro-inflammatory cytokines including TNF-alpha and IL-6 (reflecting activation of the cholinergic anti-inflammatory pathway).

Clinical Evidence for Auricular Stimulation

Epilepsy. The NEMOS device received European approval based on trials showing reduced seizure frequency in drug-resistant epilepsy patients. While effect sizes were modest compared with implanted VNS, the non-invasive nature of the approach makes it a reasonable first step before considering surgical implantation.

Depression. The TREAT-tVNS trial and subsequent studies have shown that daily taVNS over 12 weeks produces significant improvements in depression scores, with response rates comparable to some pharmacological treatments. The mechanism appears to involve modulation of the locus coeruleus-norepinephrine system and default mode network connectivity.

Inflammation. Auricular VNS has been shown to reduce inflammatory markers in healthy volunteers and in patients with rheumatoid arthritis. A 2024 study in Brain Stimulation demonstrated that taVNS reduced post-operative inflammation markers when applied perioperatively, suggesting clinical utility beyond chronic conditions.

Pain. Auricular VNS has shown benefit in chronic migraine, fibromyalgia, and endometriosis-related pain in preliminary trials. The analgesic mechanism likely involves both descending pain modulation from brainstem nuclei and anti-inflammatory effects in peripheral tissues.

Practical Stimulation Approaches

Device-based taVNS. Purpose-built taVNS devices deliver calibrated electrical pulses (typically 20 to 30 Hz, 200 to 300 microsecond pulse width) through ear clips or custom electrodes positioned at the cymba conchae. Sessions typically last 30 to 60 minutes, once or twice daily. These devices provide controlled, reproducible stimulation and are used in clinical trials. Consumer-grade taVNS devices are increasingly available, though quality and safety standards vary.

Manual stimulation. Gentle, sustained pressure or circular massage at the cymba conchae — the ridge just above your ear canal opening, not the earlobe — can produce mild vagal activation. The effect is less intense and less reproducible than electrical stimulation, but it is free, requires no equipment, and can be performed anywhere. Apply firm but comfortable pressure for 30 to 60 seconds per side. Some people notice a subtle change in breathing depth or a sensation of relaxation; others feel little.

Ear seeds and acupressure beads. Small beads taped to the cymba conchae provide continuous low-level pressure stimulation. While the evidence base is thinner than for electrical taVNS, a 2021 randomised trial found that auricular acupressure at vagal points reduced anxiety scores in pre-surgical patients compared with sham placement at non-vagal ear points.

Limitations and Realistic Expectations

Auricular vagus nerve stimulation is a genuine neuromodulation technique with real physiological effects, but it is not a substitute for implanted VNS in conditions that require it (drug-resistant epilepsy, treatment-resistant depression with severe impairment). The signal delivered through the skin and cartilage of the ear is attenuated compared with direct electrical contact with the cervical vagus nerve. Effect sizes in clinical trials are generally smaller than for implanted VNS.

The field also faces a specificity challenge: isolating ABVN stimulation from activation of neighbouring non-vagal nerves at the ear surface is difficult, and the optimal stimulation parameters (frequency, intensity, pulse width, session duration) have not been definitively established. Different studies use different protocols, making direct comparison difficult.

That said, for a non-invasive, low-risk technique that can be self-administered, auricular vagus nerve stimulation has a stronger evidence base than most complementary approaches to autonomic health. The key is targeting the right location — the cymba conchae, not the earlobe — and maintaining realistic expectations about the magnitude of effect.

The ear is just one access point to the vagus nerve’s vast network. For the full picture of how this nerve connects your brain, gut, heart, and immune system — and what you can do about it — get the Vagus Nerve & Me eBook.

Keep reading

The Impact of Caffeine on the Vagus Nerve12 min read

Foods to Avoid for Vagus Nerve Health11 min read

Top Supplements for Vagus Nerve: Boosting Your Nervous System Health12 min read